It was a pleasure to speak with Dr Siew Eng Choon (Monash University, Malaysia) about the first RCT trial conducted in generalised pustular psoriasis (GPP). Effisayil 1 (NCT03782792) is a Phase 2 trial investigating the anti-IL-36 receptor antibody, spesolimab.
The abstract entitled ‘Design and rationale of Effisayil 1, a Phase II, multicenter, randomized, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis with an acute flare’ was presented at AAD VMX, 23-25 April, 2021.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the AAD.Â
Questions
- What is the rationale for the use of spesolimab in the treatment of patients with a GPP flare? (0:21)
- What are the challenges of testing the efficacy and safety of new therapies in GPP? (2:09)
- How does the design and clinical endpoints of the Effisayil 1 study aim to overcome these challenges? (4:52)
Disclosures: Dr Siew Eng Choon has received honoraria for serving as a consultant, advisory board member, and/or speaker for AbbVie, Boehringer Ingelheim, Janssen, Leo, Eli Lilly, Leo, Novartis, Pfizer, GlaxoSmithKline, UCB, MSD and Wyeth.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the AAD VMX 2021.
